- Home
- AURE vs MCRB Comparison
AURE vs MCRB Comparison
Compare AURE & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AURE | MCRB |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.1M | 41.2M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | AURE | MCRB |
|---|---|---|
| Price | $1.04 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 65.9K | ★ 71.1K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $2.00 |
| 52 Week High | $3.53 | $29.98 |
Technical Indicators
Market Signals| Indicator | AURE | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 18.01 |
| Support Level | $1.00 | N/A |
| Resistance Level | $1.11 | $9.53 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 69.23 | 4.90 |
Price Performance
Historical ComparisonAbout AURE Prestige Wealth Inc. Class A Ordinary Shares
Aurelion Inc is a publicly traded company building a digital gold risk and technology infrastructure around XAUT, on-chain gold backed by physical LBMA bars. XAUT combines the stability of physical gold with the efficiency of blockchain, giving investors access to a tokenized gold reserve that could serve as a hedge against inflation, currency devaluation, and crypto volatility. In parallel with building a business around tokenized gold, Aurelion provides wealth and asset management services.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.